**Author details**

Omkar L. Patkar1,2, Arnauld Belmer1,2 and Selena E. Bartlett1,2\*

\*Address all correspondence to: selena.bartlett@qut.edu.au

1 Translational Research Institute, Queensland University of Technology, Brisbane, Australia

2 Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technolo‐ gy, Brisbane, Australia

## **References**


[8] Yorgason JT, FerrisMJ, Steffensen SC, Jones SR. Frequency‐dependent effects of ethanol on dopamine release in the nucleus accumbens. Alcoholism: Clinical and Experimen‐ tal Research. 2014;38(2):438–47.

**Author's contributions**

the manuscript.

**Author details**

gy, Brisbane, Australia

217–38.

**References**

All authors have been involved in the preparation and have approved the submitted manu‐ script. Omkar Patkar was the lead author and responsible for conducting the literature review and writing the manuscript. Arnauld Belmer assisted in writing and editing the manuscript. As the senior author, Selena Bartlett supervised Omkar Patkar's work, reviewed, and edited

1 Translational Research Institute, Queensland University of Technology, Brisbane, Australia

2 Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technolo‐

[1] Gnanavel S, Robert RS. Diagnostic and Statistical Manual of Mental Disorders, fifth

[2] Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and

[3] Trull TJ, Verges A, Wood PK, Jahng S, Sher KJ. The structure of Diagnostic and Statistical Manual of Mental Disorders (4th edition, text revision) personality disor‐ der symptoms in a large national sample. Personal Disorders. 2012;3(4):355–69.

[4] Gilpin NW, Koob GF. Neurobiology of alcohol dependence: focus on motivational mechanisms. Alcohol Research & Health: The Journal of the National Institute on

[5] Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology: Official Publication ofthe American College of Neuropsychopharmacology. 2010;35(1):

[7] Harris RA, Brodie MS, Dunwiddie TV. Possible substrates of ethanol reinforcement: GABA and dopamine. Annals of the New York Academy of Sciences. 1992;654:61–9.

[6] Koob GF. A role for brain stress systems in addiction. Neuron. 2008;59(1):11–34.

edition, and the impact of events scale—revised. Chest. 2013;144(6):1974.

alcohol‐use disorders. The Lancet. 2009;373(9682):2223–33.

Alcohol Abuse and Alcoholism. 2008;31(3):185–95.

Omkar L. Patkar1,2, Arnauld Belmer1,2 and Selena E. Bartlett1,2\*

\*Address all correspondence to: selena.bartlett@qut.edu.au

126 Recent Advances in Drug Addiction Research and Clinical Applications


[34] Del Re AC, Maisel N, Blodgett J, Finney J. The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: a multivariate meta‐analysis. Alcoholism: Clinical and Experimental Research. 2013;37(6):1064–8.

[20] Krentzman AR, Farkas KJ, Townsend AL. Spirituality, religiousness, and alcoholism treatment outcomes: a comparison between black and white participants. Alcoholism

[21] Tonigan JS, Rynes KN, McCrady BS. Spirituality as a change mechanism in 12‐step programs: a replication, extension, and refinement. Substance Use & Misuse.

[22] Bogenschutz MP, Rice SL, Tonigan JS, Vogel HS, Nowinski J, Hume D, Arenella PB. 12‐Step facilitation for the dually diagnosed: a randomized clinical trial. Journal of

[23] Anderson DJ, McGovern JP, DuPont RL. The origins of the Minnesota model of addiction treatment – a first person account. Journal of Addictive Diseases. 1999;18(1):

[24] Huebner RB, Kantor LW. Advances in alcoholism treatment. Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse and Alcoholism.

[25] Project MATCH secondary a priori hypotheses. Project MATCH Research Group.

[26] Gueorguieva R, Wu R, Donovan D, Rounsaville BJ, Couper D, Krystal JH, O'Malley SS. Naltrexone and combined behavioral intervention effects on trajectories of drinking in

[27] Kranzler HR, Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcoholism: Clinical and Experimental Research. 2001;25(9):1335–41.

[29] Acamprosate campral for alcoholism. Medical Letter on Drugs and Therapeutics.

[30] De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence‐promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19(6):

[31] Spanagel R, Vengeliene V, Jandeleit B, Fischer W‐N, Grindstaff K, Zhang X, Gallop MA, Krstew EV, Lawrence AJ, Kiefer F. Acamprosate produces its anti‐relapse effects via calcium. Neuropsychopharmacology: Official Publication of the American College of

[32] Yahn SL, Watterson LR, Olive MF. Safety and efficacy of acamprosate for the treat‐ ment of alcohol dependence. Substance Abuse: Research and Treatment. 2013;7:1–12.

[33] Hoque MM, Hossain KJ, Kamal MM, Akhtaruzzaman M. Naltrexone in drug addic‐ tion: significance in the prevention of relapse. Mymensingh Medical Journal. 2009;18(1

the COMBINE study. Drug and Alcohol Dependence. 2010;107(2–3):221–9.

Treatment Quarterly. 2010;28(2):128–50.

128 Recent Advances in Drug Addiction Research and Clinical Applications

Substance Abuse Treatment. 2014;46(4):403–11.

2013;48(12):1161–73.

107–14.

2011;33(4):295–9.

2005;47(1199):1–3.

517–37.

Suppl):S56–65.

Addiction. 1997;92(12):1671–98.

[28] Acamprosate. Drugs in R&D. 2002;3(1):13–8.

Neuropsychopharmacology. 2014;39(4):783–91.


[57] Gallant D. The serotonin system and alcoholism: basic research and clinical problems. Alcoholism: Clinical and Experimental Research. 1993;17(6):1345.

[44] Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy‐drinking smokers. Psychopharmacology. 2012;223(3):

[45] Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid‐Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, Scott C, Stout R. A double‐blind, placebo‐controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. Journal of Addiction Medicine.

[46] Osborn MD, Lowery JJ, Skorput AGJ, Giuvelis D, Bilsky EJ. In vivo characterization of the opioid antagonist nalmefene in mice. Life Sciences. 2010;86(15–16):624–30.

[47] Robin C. Alcohol use disorder: pathophysiology, effects, and pharmacologic options

[48] Mann K, Lemenager T, Hoffmann S, Reinhard I, Hermann D, Batra A, Berner M, Wodarz N, Heinz A, Smolka MN, Zimmermann US, Wellek S, Kiefer F, AntonRF, Team PS. Results of a double‐blind, placebo‐controlled pharmacotherapy trial in alcohol‐ ism conducted in Germany and comparison with the US COMBINE study. Addiction

[49] Sidana AK, Mangla D. Unusual side effects with acamprosate. Indian Journal of

[50] Hulse GK. Improving clinical outcomes for naltrexone as a management of problem

[51] Waal H, Christophersen AS, Frogopsahl G, Olsen LH, Morland J. [Naltrexone im‐

[52] Weiss RD. Pharmacotherapy of alcohol dependence: how and when to use disulfir‐

[53] Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, et al. Disulfiram treatment of alcoholism. A

[54] Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today?

[55] Gorelick DA. Serotonin uptake blockers and the treatment of alcoholism. Recent Developments in Alcoholism: An Official Publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on

[56] George FR. Pharmacotherapy in alcoholism treatment: integrating and understand‐ ing the use of serotonin reuptake inhibitors. Alcohol and Alcoholism (Oxford,

Veterans Administration cooperative study. JAMA. 1986;256(11):1449–55.

alcohol use. British Journal of Clinical Pharmacology. 2013;76(5):632–41.

plants – a pilot project]. Tidsskr Nor Laegeforen. 2003;123(12):1660–1.

am and naltrexone. Current Psychiatry. 2002;1(1):51–60.

299–306.

2013;7(4):277–86.

for treatment. 2014;5:1–12.

130 Recent Advances in Drug Addiction Research and Clinical Applications

Biology. 2013;18(6):937–46.

Psychiatry. 2007;49(2):143.

Addiction. 2004;99(1):21–4.

Alcoholism. 1989;7:267–81.

Oxfordshire) Supplement. 1994;2:537–43.


[80] Sari Y. Role of 5‐hydroxytryptamine 1B (5‐HT1B) receptors in the regulation of ethanol intake in rodents. Journal of Psychopharmacology. 2013;27(1):3–12.

[68] Tran L, Lasher BK, Young KA, Keele NB. Depletion of serotonin in the basolateral amygdala elevates glutamate receptors and facilitates fear‐potentiated startle.

[69] Roozendaal B, Nguyen BT, Power AE, McGaugh JL. Basolateral amygdala noradre‐ nergic influence enables enhancement of memory consolidation induced by hippo‐ campal glucocorticoid receptor activation. Proceedings of the National Academy of

[70] Pare D. Role of the basolateral amygdala in memory consolidation. Progress in

[71] Zhang J, Muller JF, McDonald AJ. Noradrenergic innervation of pyramidal cells in the

[72] Commons KG, Connolley KR, Valentino RJ. A neurochemically distinct dorsal raphe‐ limbic circuit with a potential role in affective disorders. Neuropsychopharmacology: Official Publication ofthe American College of Neuropsychopharmacology. 2003;28(2):

[73] Le AD, Harding S, Juzytsch W, Fletcher PJ, Shaham Y. The role of corticotropin‐ releasing factor in the median raphe nucleus in relapse to alcohol. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience. 2002;22(18):7844–9.

[74] Bonkale WL, Turecki G, Austin MC. Increased tryptophan hydroxylase immunoreac‐ tivity in the dorsal raphe nucleus of alcohol‐dependent, depressed suicide subjects is

[75] Ketcherside A, Mathews I, Filbey F. The serotonin link between alcohol use and 25 affective disorders. Journal of Addiction and Prevention. 2013;1(2).3p. n/a-n/a.

[76] Andrade AL, Abrahao KP, Goeldner FO, Souza‐Formigoni ML. Administration of the 5‐HT2C receptor antagonist SB‐242084 into the nucleus accumbens blocks the expression of ethanol‐induced behavioral sensitization in Albino Swiss mice.

[77] DingZM, Oster SM, Hauser SR, Toalston JE, BellRL, McBrideWJ, RoddZA. Synergistic self‐administration of ethanol and cocaine directly into the posterior ventral tegmen‐ tal area: involvement of serotonin‐3 receptors. The Journal of Pharmacology and

[78] Burnett EJ, Grant KA, Davenport AT, Hemby SE, Friedman DP. The effects of chron‐ ic ethanol self‐administration on hippocampal 5‐HT 1A receptors in monkeys. Drug and

[79] Kasper JM. Characterization of the effects of novel 5‐HT2C receptor agonists on neurotransmission and voluntary alcohol consumption in rats. Thesis, University of

Sciences of the United States of America. 1999;96(20):11642–7.

rat basolateral amygdala. Neuroscience. 2013;228:395–408.

restricted to the dorsal subnucleus. Synapse. 2006;60(1):81–5.

Translational Psychiatry. 2013;3:e298.

132 Recent Advances in Drug Addiction Research and Clinical Applications

Neurobiology. 2003;70(5):409–20.

Neuroscience. 2011;189:178–86.

Experimental Therapeutics. 2012;340(1):202–9.

Alcohol Dependence. 2014;136:135–142.

Florida; 2013.

206–15.


[103] Funk CK, Koob GF. A CRF(2) agonist administered into the central nucleus of the amygdala decreases ethanol self‐administration in ethanol‐dependent rats. Brain Research. 2007;1155:172–8.

[92] Lemos JC, Wanat MJ, Smith JS, Reyes BA, Hollon NG, Van Bockstaele EJ, Chavkin C, Phillips PE. Severe stress switches CRF action in the nucleus accumbens from appeti‐

[93] Huang MM, Overstreet DH, Knapp DJ, Angel R, Wills TA, Navarro M, Rivier J, Vale W, Breese GR. Corticotropin‐releasing factor (CRF) sensitization of ethanol withdraw‐ al‐induced anxiety‐like behavior is brain site specific and mediated by CRF‐1 recep‐ tors: relation to stress‐induced sensitization. The Journal of Pharmacology and

[94] Hauger RL, Risbrough V, Oakley RH, Olivares‐Reyes JA, Dautzenberg FM. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Annals of the New

[95] Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. American Journal of Psychiatry. 2007;164(8):1149–59.

[96] Hammack SE, Guo JD, Hazra R, Dabrowska J, Myers KM, Rainnie DG. The response of neurons in the bed nucleus of the stria terminalis to serotonin: implications for anxiety. Progress in Neuro‐Psychopharmacology & Biological Psychiatry. 2009;33(8):

[97] Wenzel JM, Cotten SW, Dominguez HM, Lane JE, Shelton K, Su ZI, Ettenberg A. Noradrenergic beta‐receptor antagonism within the central nucleus of the amygdala or bed nucleus of the stria terminalis attenuates the negative/anxiogenic effects of cocaine. The Journal of Neuroscience: The Official Journal of the Society for Neuro‐

[98] Flavin SA, Winder DG. Noradrenergic control of the bed nucleus of the stria termina‐

[99] Leri F, Flores J, Rodaros D, Stewart J. Blockade of stress‐induced but not cocaine‐ induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala. The Journal of Neuro‐ science: The Official Journal of the Society for Neuroscience. 2002;22(13):5713–8.

[100] Le AD, Funk D, Coen K, Li Z, Shaham Y. Role of corticotropin‐releasing factor in the median raphe nucleus in yohimbine‐induced reinstatement of alcohol seeking in rats.

[101] Dzung Le A, Funk D, Harding S, Juzytsch W, Fletcher PJ. The role of noradrenaline and 5‐hydroxytryptamine in yohimbine‐induced increases in alcohol‐seeking in rats.

[102] Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y, Le A. The CRF1 receptor antagonist antalarmin attenuates yohimbine‐induced increases in operant alcohol self‐administration and reinstatement of alcohol seeking in rats. Psychophar‐

lis in stress and reward. Neuropharmacology. 2013;70:324–30.

tive to aversive. Nature. 2012;490(7420):402–6.

134 Recent Advances in Drug Addiction Research and Clinical Applications

Experimental Therapeutics. 2010;332(1):298–307.

York Academy of Sciences. 2009;1179:120–43.

1309–20.

science. 2014;34(10):3467–74.

Addiction Biology. 2013;18(3):448–51.

Psychopharmacology. 2009;204(3):477–88.

macology. 2007;195(3):345–55.


[129] Christian DT, Alexander NJ, Diaz MR, McCool BA. Thalamic glutamatergic afferents into the rat basolateral amygdala exhibit increased presynaptic glutamate function following withdrawal from chronic intermittent ethanol. Neuropharmacology. 2013;65:134–42.

[117] Killcross S, Robbins TW, Everitt BJ. Different types of fear‐conditioned behaviour mediated by separate nuclei within amygdala. Nature. 1997;388(6640):377–80.

[118] Nomura M, Izaki Y, Takita M, Tanaka J, Hori K. Extracellular level of basolateral amygdalar dopamine responding to reversal of appetitive‐conditioned discrimina‐

[119] Ramirez DR, Savage LM. Differential involvement of the basolateral amygdala, orbitofrontal cortex, and nucleus accumbens core in the acquisition and use of reward

[120] Meil WM, See RE. Lesions of the basolateral amygdala abolish the ability of drug associated cues to reinstate responding during withdrawal from self‐administered

[121] Valizadegan F, Oryan S, Nasehi M, Zarrindast MR. Interaction between morphine and noradrenergic system of basolateral amygdala on anxiety and memory in the elevat‐ ed plus‐maze test based on a test‐retest paradigm. Archives of Iranian Medicine.

[122] Varodayan, F.P., et al., *Chronic alcohol exposure disrupts CB1 regulation of GABAergic transmission in the rat basolateral amygdala*. Addiction Biology, 2016: p. n/a-n/a.In press.

[123] Sciascia JM, Reese RM, Janak PH, Chaudhri N. Alcohol‐seeking triggered by discrete pavlovian cues is invigorated by alcohol contexts and mediated by glutamate signal‐ ing in the basolateral amygdala. Neuropsychopharmacology: Official Publication of

[124] Gass JT, Sinclair CM, Cleva RM, Widholm JJ, Olive MF. Alcohol‐seeking behavior is associated with increased glutamate transmission in basolateral amygdala and nucleus accumbens as measured by glutamate‐oxidase‐coated biosensors. Addiction Biology.

[125] Porrino LJ, Williams‐Hemby L, Whitlow C, Bowen C, Samson HH. Metabolic map‐ ping of the effects of oral alcohol self‐administration in rats. Alcoholism: Clinical and

[126] Läck AK, Diaz MR, Chappell A, DuBois DW, McCool BA. Chronic ethanol and withdrawal differentially modulate pre‐ and post‐synaptic function at glutamatergic synapses in rat basolateral amygdala. Journal of Neurophysiology. 2007;98(6):3185–96.

[127] Rassnick S, Pulvirenti L, Koob GF. Oral ethanol self‐administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus

[128] Hyytia P, Kiianmaa K. Suppression of ethanol responding by centrally administered CTOP and naltrindole in AA and Wistar rats. Alcoholism: Clinical and Experimental

the American College of Neuropsychopharmacology. 2015;40(12):2801–12.

tion in young and old rats. Brain Research. 2004;1018(2):241–6.

136 Recent Advances in Drug Addiction Research and Clinical Applications

expectancies. Behavioral Neuroscience. 2007;121(5):896–906.

cocaine. Behavioural Brain Research. 1997;87(2):139–48.

2013;16(5):281–7.

2011;16(2):215–28.

Research. 2001;25(1):25–33.

Experimental Research. 1998;22(1):176–82.

accumbens. Psychopharmacology. 1992;109(1):92–8.


ical mechanisms contributing to alcohol–stress–anxiety interactions. Alcohol. 2009;43(7):509–19.

[150] Baculis BC, Diaz MR, Valenzuela CF. Third trimester‐equivalent ethanol exposure increases anxiety‐like behavior and glutamatergic transmission in the basolateral amygdala. Pharmacology, Biochemistry, and Behavior. 2015;137:78–85.

[139] Wilden J, Hauser S, Deehanjr G, Ding Z‐M, Truitt W, Mcbride W, Rodd Z. The basolateral amygdala is a critical structure for environmental cue augmentation of

[140] Marinelli PW, Funk D, Juzytsch W, Le AD. Opioid receptors in the basolateral amygdala but not dorsal hippocampus mediate context‐induced alcohol seeking.

[141] Gass JT, Sinclair CM, Cleva RM, Widholm JJ, Olive MF. Alcohol‐seeking behavior is associated with increased glutamate transmission in basolateral amygdala and nucleus accumbens as measured by glutamate‐oxidase‐coated biosensors. Addiction Biology.

[142] Silberman Y, Matthews RT, Winder DG. A corticotropin releasing factor pathway for ethanol regulation of the ventral tegmental area in the bed nucleus of the stria terminalis. The Journal of Neuroscience: The Official Journal of the Society for

[143] Simms JA, Haass‐Koffler CL, Bito‐Onon J, Li R, Bartlett SE. Mifepristone in the central nucleus of the amygdala reduces yohimbine stress‐induced reinstatement of ethanol‐ seeking. Neuropsychopharmacology: Official Publication of the American College of

[144] Valdez GR, Sabino V, Koob GF. Increased anxiety‐like behavior and ethanol self‐ administration in dependent rats: reversal via corticotropin‐releasing factor‐2 recep‐ tor activation. Alcoholism: Clinical and Experimental Research. 2004;28(6):865–72.

[145] Maroun M, Ioannides PJ, Bergman KL, Kavushansky A, Holmes A, Wellman CL. Fear extinction deficits following acute stress associate with increased spine density and dendritic retraction in basolateral amygdala neurons. The European Journal of

[146] Rei D, Mason X, Seo J, Gräff J, Rudenko A, Wang J, Rueda R, Siegert S, Cho S, Canter RG, Mungenast AE, Deisseroth K, Tsai L‐H. Basolateral amygdala bidirectionally modulates stress‐induced hippocampal learning and memory deficits through a p25/ Cdk5‐dependent pathway. Proceedings of the National Academy of Sciences of the

[147] Rau AR, Chappell AM, Butler TR, Ariwodola OJ, Weiner JL. Increased basolateral amygdala pyramidal cell excitability may contribute to the anxiogenic phenotype induced by chronic early‐life stress. The Journal of Neuroscience: The Official Journal

[148] Zhang W, Rosenkranz JA. Repeated restraint stress increases basolateral amygdala neuronal activity in an age‐dependent manner. Neuroscience. 2012;226:459–74.

[149] Silberman Y, Bajo M, Chappell AM, Christian DT, Cruz M, Diaz MR, Kash T, Lack AK, Messing RO, Siggins GR, Winder D, Roberto M, McCool BA, Weiner JL. Neurobiolog‐

EtOH‐seeking. 2012.

138 Recent Advances in Drug Addiction Research and Clinical Applications

2011;16(2):215–28.

Neuroscience. 2013;33(3):950–60.

Neuroscience. 2013;38(4):2611–20.

Behavioural Brain Research. 2010;211(1):58–63.

Neuropsychopharmacology. 2012;37(4):906–18.

United States of America. 2015;112(23):7291–6.

of the Society for Neuroscience. 2015;35(26):9730–40.


[173] Kraus ML, Gottlieb LD, Horwitz RI, Anscher M. Randomized clinical trial of atenolol in patients with alcohol withdrawal. The New England Journal of Medicine. 1985;313(15):905–9.

[161] Ferry B, Roozendaal B, McGaugh JL. Basolateral amygdala noradrenergic influences on memory storage are mediated by an interaction between β‐ and α1‐adrenoceptors.

[162] Barak S, Liu F, Hamida SB, Yowell QV, Neasta J, Kharazia V, Janak PH, Ron D. Disruption of alcohol‐related memories by mTORC1 inhibition prevents relapse.

[163] Butler TR, Chappell AM, Weiner JL. Effect of beta3 adrenoceptor activation in the basolateral amygdala on ethanol seeking behaviors. Psychopharmacology. 2014;231(1):

[164] Hoffman PL, Valverius P, Kwast M, Tabakoff B. Comparison of the effects of ethanol on beta‐adrenergic receptors in heart and brain. Alcohol and Alcoholism (Oxford,

[165] Rainnie DG. Serotonergic modulation of neurotransmission in the rat basolateral

[166] Cheng LL, Wang SJ, Gean PW. Serotonin depresses excitatory synaptic transmission and depolarization‐evoked Ca2+ influx in rat basolateral amygdala via 5‐HT1A

[167] de Andrade Strauss CV, Vicente MA, Zangrossi Jr H. Activation of 5‐HT1A receptors in the rat basolateral amygdala induces both anxiolytic and antipanic‐like effects.

[168] Nevo I, Langlois X, Laporte AM, Kleven M, Koek W, Lima L, Maudhuit C, Martres MP, HamonM. Chronic alcoholization alters the expression of 5‐HT1A and 5‐HT1B receptor subtypes in rat brain. The European Journal of Pharmacology. 1995;281(3):229–39.

[169] Christianson JP, Ragole T, Amat J, Greenwood BN, Strong PV, Paul ED, Fleshner M, Watkins LR, Maier SF. 5‐Hydroxytryptamine 2C receptors in the basolateral amygda‐ la are involved in the expression of anxiety after uncontrollable traumatic stress.

[170] Gonzalez LE, Andrews N, File SE. 5‐HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the

[171] McCool BA, Frye GD, Pulido MD, Botting SK. Effects of chronic ethanol consump‐ tion on rat GABA(A) and strychnine‐sensitive glycine receptors expressed by lateral/

[172] Patkar, O.L., et al., *The antihypertensive drug pindolol attenuates long-term but not shortterm binge-like ethanol consumption in mice*. Addiction Biology, 2016: p. n/a-n/a. In

basolateral amygdala neurons. Brain Research. 2003;963(1–2):165–77.

receptors. The European Journal of Neuroscience. 1998;10(6):2163–72.

Journal of Neuroscience. 1999;19(12):5119–23.

Nature Neuroscience. 2013;16(8):1111–7.

140 Recent Advances in Drug Addiction Research and Clinical Applications

Oxfordshire) Supplement. 1987;1:749–54.

Behavioural Brain Research. 2013;246:103–10.

Biological Psychiatry. 2010;67(4):339–45.

press. 2016.

elevated plus‐maze. Brain Research. 1996;732(1–2):145–53.

amygdala. Journal of Neurophysiology. 1999;82(1):69–85.

293–303.

